Chapter 36: Hemostasis and Blood Coagulation

Written By: Razaullah Khattak (DPT Medical Professional)

Student Source Reference: Guyton and Hall Textbook of Medical Physiology

Chapter: 36

To read more check out Chapter 19:

https://mednotesbyrazaullah.blogspot.com/2026/08/chapter-19-role-of-kidneys-in-long-term.html

Events in Hemostasis and Vascular Constriction

Hemostasis refers to the physiological process that prevents excessive blood loss following vascular injury. When a blood vessel wall is severed or ruptured, the body immediately initiates a series of coordinated local responses to restrict bleeding, form a temporary barrier, and permanently seal the damaged area.

The primary immediate response to vascular injury is localized vasoconstriction, which slows blood flow through the damaged vessel. This vascular spasm occurs through local myogenic reflexes, autacoid factors released from injured tissues and platelets (such as thromboxane A2), and pain-induced neural reflexes. The degree of spasm correlates directly with the severity of tissue trauma.

• Hemostasis means prevention of blood loss.
• Vascular injury triggers immediate smooth muscle contraction.
• Vasoconstriction instantaneously reduces local blood flow.
• Local myogenic spasms initiate vascular constriction.
• Damaged tissues release local autacoid factors.
• Pain impulses trigger nervous reflexes causing vasoconstriction.
• Direct vascular damage causes strong myogenic contraction.
• Platelets release thromboxane A2 to constrict vessels.
• Severe vessel trauma causes greater vascular spasm.
• Vascular spasms last for minutes or hours.
• Spasms allow time for clotting mechanisms.

Physical and Chemical Characteristics of Platelets

Platelets, also known as thrombocytes, are small, anucleate cell fragments derived from giant megakaryocytes in the bone marrow. These minute structures circulate in large numbers and contain complex intracellular machinery capable of active contraction, factor synthesis, and chemical signaling despite lacking a nucleus.

The outer membrane of a platelet features a specialized glycoprotein coat that prevents adhesion to normal vessel walls while promoting firm attachment to exposed collagen in injured tissues. Additionally, platelet membrane phospholipids play an essential role in activating multiple steps of the blood coagulation cascade during vascular repair.

• Platelets are also called thrombocytes.
• Platelets are small discs, one to four micrometers.
• Megakaryocytes in bone marrow produce platelets.
• Megakaryocyte fragmentation forms platelets in blood.
• Normal platelet count is 150,000 to 300,000 per microliter.
• Platelets lack nuclei and cannot reproduce.
• Cytoplasm contains contractile proteins actin and myosin.
• Thrombosthenin protein causes active platelet contraction.
• Endoplasmic reticulum stores large calcium ion quantities.
• Mitochondria synthesize cellular ATP and ADP.
• Enzyme systems synthesize local prostaglandin hormones.
• Platelets store fibrin-stabilizing factor for clotting.
• Platelets release growth factor for tissue repair.
• Glycoprotein coat repulses normal vascular endothelium.
• Glycoproteins adhere strongly to exposed collagen.
• Membrane phospholipids activate blood-clotting stages.
• Platelets have half-lives of eight to twelve days.
• Tissue macrophages eliminate old circulating platelets.
• Spleen macrophages remove over half of platelets.

Mechanism of the Platelet Plug

When blood vessels experience minor endothelial damage, platelet plug formation serves as the primary mechanism to arrest bleeding. Exposed subendothelial collagen fibers trigger immediate structural and functional changes in circulating platelets, transforming them into sticky, secretory units that aggregate at the injury site.

Activated platelets extend pseudopods, contract forcefully, and release key chemical mediators including adenosine diphosphate (ADP) and thromboxane A2. These substances recruit and activate neighboring platelets in a self-amplifying positive feedback loop, rapidly forming a plug that is subsequently reinforced by fibrin threads.

• Platelet plugs seal small daily vascular holes.
• Contact with collagen alters platelet characteristics drastically.
• Activated platelets swell and extend numerous pseudopods.
• Contractile proteins contract to release stored granules.
• Platelets adhere to collagen and von Willebrand factor.
• Activated platelets secrete large quantities of ADP.
• Platelet enzymes synthesize thromboxane A2.
• ADP and thromboxane A2 activate nearby platelets.
• Platelet stickiness causes cells to adhere together.
• Successive platelet recruitment forms a local plug.
• Initial platelet plug is relatively loose.
• Fibrin threads attach tightly to platelets.
• Fibrin constructs an unyielding final plug.
• Platelets fuse with endothelium to repair micro-ruptures.
• Low platelet counts cause thousands of daily hemorrhages.

Stages and Timing of Blood Coagulation

Blood coagulation is the third major mechanism of hemostasis, converting fluid blood into a solid gel meshwork. The clotting process initiates within seconds following severe vascular trauma and within two minutes after minor tissue injury, relying on activator substances from damaged tissues and platelets.

Once a clot forms, it gradually undergoes retraction over 20 to 60 minutes, pulling the torn edges of the blood vessel closer together. This mechanical compression expresses fluid serum which lacks clotting factors and stabilizes the physical barrier against continued hemorrhage.

• Severe trauma initiates clotting in 15 to 20 seconds.
• Minor trauma initiates clotting in one to two minutes.
• Damaged tissues and platelets release clotting activators.
• Clots fill broken vessel openings in three to six minutes.
• Clots undergo retraction after 20 to 60 minutes.
• Retraction pulls broken vessel edges together.
• Clot retraction expresses fluid called serum.
• Serum lacks fibrinogen and major clotting factors.
• Serum cannot undergo further blood clotting.
• Platelets are necessary for proper clot retraction.
• Defective retraction indicates low circulating platelets.
• Platelet contractile proteins compress the fibrin mesh.
• Thrombin and calcium ions accelerate clot contraction.

Fibrous Organization or Dissolution of Blood Clots

Following its initial formation, a blood clot follows one of two distinct physiological pathways based on its location and tissue necessity. In small vascular wounds, the clot undergoes fibrous organization, where invading cells permanently replace the meshwork with structural connective tissue.

Alternatively, when blood escapes into unwanted tissue spaces, the body activates intrinsic enzymatic systems to break down the temporary barrier. Platelet-derived growth factors stimulate structural repair, while local fibrinolytic enzymes ensure that redundant intravascular or extravascular clots are completely cleared.

• Clots either undergo fibrous invasion or dissolution.
• Fibroblasts invade small vessel clots within hours.
• Platelet growth factor promotes fibroblast invasion.
• Complete fibrous organization occurs in one to two weeks.
• Unneeded tissue clots undergo enzymatic dissolution.
• Specialized enzymes dissolve unnecessary extravascular clots.

General Mechanism of Blood Coagulation

The fluidity of circulating blood is maintained by a delicate balance between active procoagulants and dominant anticoagulants. Vascular injury disrupts this balance by activating procoagulant proteins, triggering a multi-step enzymatic cascade that culminates in stable clot formation.

The coagulation cascade operates through three general steps: the formation of prothrombin activator, the enzymatic conversion of prothrombin into thrombin, and the subsequent conversion of soluble fibrinogen into insoluble fibrin fibers that trap cellular elements.

• Blood contains over fifty coagulation-related substances.
• Procoagulants promote blood coagulation processes.
• Anticoagulants inhibit blood coagulation processes.
• Anticoagulants normally predominate in circulating blood.
• Vascular damage activates local procoagulant substances.
• Clotting involves a complex cascading chemical reaction.
• Coagulation cascade generates prothrombin activator complex.
• Prothrombin activator catalyzes prothrombin into thrombin.
• Thrombin converts soluble fibrinogen into insoluble fibrin.
• Fibrin fibers enmesh platelets and blood cells.

Conversion of Prothrombin to Thrombin

The conversion of prothrombin to active thrombin represents the central rate-limiting phase of blood coagulation. Prothrombin activator, formed via extrinsic or intrinsic pathways, catalyzes this cleavage rapidly in the presence of ionized calcium and active platelet membrane surfaces.

Prothrombin is an unstable plasma protein continuously synthesized by the liver through a process requiring vitamin K. Because thrombin generation acts as the key enzymatic driver for all subsequent steps, hepatic failure or vitamin K deficiency severely impairs blood clotting ability.

• Prothrombin activator forms after vessel rupture.
• Ionic calcium converts prothrombin into thrombin.
• Thrombin causes polymerization of fibrinogen molecules.
• Prothrombin activator formation is the rate-limiting step.
• Platelet surface receptors bind circulating prothrombin.
• Prothrombin is an alpha2-globulin plasma protein.
• Prothrombin molecular weight is 68,700.
• Normal plasma prothrombin concentration is 15 mg/dl.
• Thrombin molecular weight is 33,700.
• Liver continually synthesizes plasma prothrombin.
• Prothrombin levels drop rapidly during liver failure.
• Vitamin K is required for hepatic prothrombin synthesis.
• Vitamin K deficiency leads to bleeding tendencies.

Conversion of Fibrinogen to Fibrin and Clot Stabilization

Fibrinogen is a high-molecular-weight plasma protein produced by the liver that serves as the building block for the final blood clot. Thrombin acts proteolytically on fibrinogen, cleaving small peptides to yield fibrin monomers that spontaneously aggregate into long, non-covalently bound strands.

Initially, these polymer strands form a relatively weak, loose mesh. To grant structural integrity to the clot, thrombin simultaneously activates fibrin-stabilizing factor (Factor XIII), which catalyzes covalent cross-linking between adjacent fibrin fibers to create a dense, resistant network.

• Fibrinogen molecular weight is 340,000.
• Normal plasma fibrinogen concentration is 100 to 700 mg/dl.
• Liver continuously synthesizes circulating fibrinogen.
• Large fibrinogen molecules rarely leak into normal interstitial fluid.
• Increased capillary permeability allows tissue fluid clotting.
• Thrombin removes low-molecular-weight peptides from fibrinogen.
• Proteolysis creates single fibrin monomer molecules.
• Fibrin monomers polymerize rapidly into long fibrin fibers.
• Early fibrin polymers hold together by weak hydrogen bonding.
• Early non-cross-linked fibrin clots break apart easily.
• Fibrin-stabilizing factor cross-links adjacent fibrin fibers.
• Platelets release additional stored fibrin-stabilizing factor.
• Thrombin activates inactive fibrin-stabilizing factor.
• Activated Factor XIII creates strong covalent bonds.
• Cross-linking adds three-dimensional strength to fibrin meshwork.
• Fibrin meshwork entraps blood cells, platelets, and plasma.

Positive Feedback of Clot Formation

Once a blood clot begins to form, it initiates a powerful positive feedback mechanism that accelerates further clotting in the immediate vicinity. Thrombin itself acts as the primary driver of this auto-catalytic amplification loop, expanding the clot until local vessel leakage is successfully halted.

Thrombin enhances its own production by proteolytically activating multiple upstream clotting factors, including Factors V, VIII, IX, XI, and XII, while simultaneously promoting platelet aggregation. This explosive process ensures rapid seal formation at the site of vascular injury.

• Developing blood clots initiate positive feedback loops.
• Thrombin exhibits proteolytic actions on multiple clotting factors.
• Thrombin converts additional prothrombin into active thrombin.
• Thrombin accelerates actions of Factors VIII, IX, X, XI, XII.
• Thrombin enhances local blood platelet aggregation.
• Critical thrombin levels trigger rapid explosive clot growth.
• Clot growth continues until blood leakage completely ceases.

Extrinsic Pathway for Initiating Coagulation

The extrinsic pathway for initiating blood clotting is triggered when traumatized vascular walls or extravascular tissues come into direct contact with blood. Damaged tissues release tissue factor (tissue thromboplastin), a complex composed of membrane phospholipids and a proteolytic lipoprotein enzyme.

This pathway proceeds rapidly and explosively through a brief series of enzymatic steps involving Factor VII, Factor X, and Factor V. In the presence of calcium ions, activated Factor X combines with phospholipids and Factor V to form prothrombin activator, inducing clot formation in as little as 15 seconds.

• Extrinsic pathway begins with traumatized tissue contact.
• Traumatized tissues release complex called tissue factor.
• Tissue factor contains phospholipids and proteolytic lipoproteins.
• Tissue factor forms a complex with Factor VII.
• Tissue factor-Factor VII complex activates Factor X.
• Calcium ions are required to form activated Factor X.
• Activated Factor X combines immediately with tissue phospholipids.
• Activated Factor X combines with Factor V.
• Factor Xa, Factor V, and phospholipids form prothrombin activator.
• Thrombin proteolytically activates inactive Factor V.
• Activated Factor V strongly accelerates prothrombin conversion.
• Activated Factor X is the actual protease splitting prothrombin.
• Extrinsic pathway acts explosively during severe trauma.
• Extrinsic clotting can occur in 15 seconds.

Intrinsic Pathway for Initiating Coagulation

The intrinsic pathway initiates directly within the vascular space when blood encounters exposed subendothelial collagen or damaged endothelial surfaces. This contact alters Factor XII and triggers platelet activation, setting off a sequential enzymatic cascade involving multiple plasma proteins.

Activated Factor XII sequentially converts Factor XI and Factor IX into their active enzymatic forms. Activated Factor IX then works in concert with activated Factor VIII, platelet factor 3, and calcium ions to activate Factor X, which ultimately yields prothrombin activator via the same terminal mechanism as the extrinsic pathway.

• Intrinsic pathway begins with direct blood trauma.
• Contact with subendothelial collagen activates Factor XII.
• Contact with wettable surfaces converts Factor XII into XIIa.
• Damaged platelets release platelet factor 3 phospholipids.
• Activated Factor XII enzymatically activates Factor XI.
• High-molecular-weight kininogen and prekallikrein accelerate XI activation.
• Activated Factor XI enzymatically activates Factor IX.
• Activated Factor IX works with activated Factor VIII.
• Factor IXa and VIIIa activate Factor X on platelet membranes.
• Classic hemophilia results from Factor VIII deficiency.
• Thrombocytopenia causes deficiency in platelet phospholipids.
• Activated Factor X combines with Factor V and phospholipids.
• Prothrombin activator cleavage forms thrombin within seconds.
• Intrinsic pathway is slower, requiring one to six minutes.

Role of Calcium Ions in Coagulation

Calcium ions (Ca^{++}) are strictly required for almost every enzymatic reaction within both the extrinsic and intrinsic coagulation pathways, except for the initial steps of intrinsic activation. Without adequate free calcium ions, blood clotting cannot occur through either mechanism.

In the human body, physiological calcium levels rarely drop low enough to inhibit coagulation kinetics. However, outside the body, blood can be effectively prevented from clotting by adding deionizing agents like citrate or precipitating agents like oxalate to lower free calcium below the necessary threshold.

• Calcium ions are required for most clotting reactions.
• First two intrinsic steps do not require calcium.
• Absence of calcium ions prevents all blood clotting.
• In vivo calcium levels rarely fall low enough to stop clotting.
• Citrate ions deionize calcium to prevent blood clotting.
• Oxalate ions precipitate calcium to block clotting reactions.

Intravascular Anticoagulants and Endothelial Protections

Under normal physiological conditions, circulating blood remains fluid due to smooth vessel walls, protective endothelial coatings, and active plasma anticoagulants. Smooth endothelial cell surfaces prevent contact activation of Factor XII and platelets, while the glycocalyx repels clotting factors.

Additionally, endothelial cells express thrombomodulin, a membrane-bound protein that binds circulating thrombin. The resulting thrombomodulin-thrombin complex activates Protein C, an anticoagulant enzyme that inactivates Factors Va and VIIIa, while fibrin fibers and antithrombin III continuously absorb and neutralize free thrombin.

• Smooth endothelial surfaces prevent contact activation.
• Endothelial glycocalyx layer repels circulating clotting factors.
• Membrane-bound thrombomodulin binds free circulating thrombin.
• Thrombomodulin-thrombin complex activates plasma Protein C.
• Activated Protein C inactivates Factors V and VIII.
• Endothelial damage destroys smoothness and protective glycocalyx.
• Damaged endothelium exposes subendothelial collagen fibers.
• Fibrin fibers adsorb 85 to 90 percent of formed thrombin.
• Adsorption prevents excessive spread of the clot.
• Antithrombin III inactivates unabsorbed circulating thrombin.
• Antithrombin III blocks thrombin action over 12 to 20 minutes.

Physiological and Clinical Actions of Heparin

Heparin is a naturally occurring, highly negatively charged conjugated polysaccharide that functions as a powerful biological anticoagulant. Although present in low concentrations normally, it is widely utilized as a pharmacological agent to prevent or treat intravascular clotting.

By itself, heparin exhibits minimal anticoagulant activity; however, upon binding to antithrombin III, it enhances the speed and effectiveness of antithrombin III by a hundredfold to a thousandfold. Basophilic mast cells in pericapillary tissues, particularly in the lungs and liver, continuously synthesize and secrete heparin to prevent localized clot expansion.

• Heparin is a highly negatively charged polysaccharide.
• Heparin alone exhibits minimal direct anticoagulant activity.
• Heparin combines with antithrombin III to increase its activity.
• Heparin increases antithrombin III effectiveness up to thousandfold.
• Heparin-antithrombin III complex removes free thrombin instantaneously.
• Complex inactivates activated Factors IX, X, XI, XII.
• Pericapillary mast cells continually produce natural heparin.
• Blood basophils release small heparin quantities into plasma.
• Lung and liver capillaries contain abundant mast cells.
• Heparin prevents clot growth in slow venous circulations.

Lysis of Blood Clots via the Plasmin System

The body possesses a specialized enzymatic system dedicated to clearing unneeded or obstructive blood clots from the vascular tree. Plasminogen, an inactive plasma euglobulin trapped within clots during formation, is converted into plasmin a potent proteolytic enzyme resembling digestive trypsin.

Slowly released tissue plasminogen activator (t-PA) from injured tissues converts trapped plasminogen into active plasmin over several days. Plasmin then digests fibrin fibers, fibrinogen, and several clotting factors, successfully re-opening occluded microvessels and clearing tissue spaces.

• Plasminogen is an inactive plasma euglobulin protein.
• Activated plasminogen becomes a proteolytic enzyme called plasmin.
• Plasmin resembles pancreatic digestive enzyme trypsin.
• Plasmin digests fibrin, fibrinogen, and Factors V, VIII, XII.
• Plasmin formation causes lysis of blood clots.
• Formed clots trap large amounts of inactive plasminogen.
• Injured tissues slowly release tissue plasminogen activator (t-PA).
• t-PA converts trapped plasminogen into active plasmin.
• Plasmin clears unnecessary clots to reopen blocked microvessels.
• Conditions Causing Excessive Human Bleeding
• Excessive clinical bleeding can arise 

Disclaimer: This content is for educational purposes only and not a substitute for professional medical advice.